DEC 08, 2019 10:20 AM PST

Parkinson's Drug Reduces Hallucinations in Dementia Patients

WRITTEN BY: Annie Lennon

Pimavanserin, also known as Nuplazid, was approved in the US to treat Parkinson’s-related psychosis in 2016. Now, new research has shown that it also works in patients with dementia-related psychosis (DRP)- something that affects 2.4 million people in the US. 

For the study, investigators recruited 392 people with DRP under double-blind, placebo-controlled conditions. Each was given a low dose of Pimavanserin for three months, with those who showed a response split into two groups. While one continued on the drug, the other was given a placebo for six months until they had a relapse or their symptoms worsened. 

Developed by pharmaceutical company Acadia, its President, Serge Stankovic, said on the results: “First, in the 12-week open-label period, pimavanserin treatment showed a meaningful reduction of the symptoms and stabilization of psychosis across all of the five clinically diagnosed subtypes evaluated. Second, in the 26-week double-blind period, patients on pimavanserin had a nearly three-fold reduction of risk of relapse compared to patients on placebo.”

With such promising results, the study was in fact put to a halt when independent monitors noticed that those in the placebo group were over twice as likely than those on the drug to worsen- at a rate of 28% compared to less than 13%. 

Generally well-tolerated by the cohort, throughout the study, researchers noticed relatively few side effects- with just 5% of those on the drug group and 4% in the control groups experiencing mild effects including headaches and urinary tract infections. Although two deaths occurred during the trial, the study’s authors say that these were unrelated to the intervention. 

Dr Jeffrey Cummings, a consultant for Acadia and one of the study’s leaders, said, “Reducing the risk of relapse of psychotic symptoms by this magnitude is an important and meaningful outcome as these are serious events which could lead to poor patient outcomes and a significant increase in caregiver burden and distress.”

Having been granted “Breakthrough Therapy” status by the FDA, Acadia hopes that it will be approved as a treatment for dementia-related psychosis in 2020, something that would make it the first FDA-approved drug for the illness.


Sources: LA Times, Medscape and WebMD

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
JAN 21, 2020
Cancer
JAN 21, 2020
How caloric restriction mimetics might prove helpful for cancer treatments
The benefits of fasting have been known to scientists and medical professionals for some time now, however for many, the reality of fasting is not alluring...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Gene Variant Could Be a Therapeutic Target For Alzheimer Disease
A variation in genetics for an individual at high-risk for Alzheimer development has defied the odds for being dementia-free way beyond anticipated. The in...
JAN 21, 2020
Cell & Molecular Biology
JAN 21, 2020
New Insight Into Chronic Pain May Help Create Novel Therapeutics
Acute pain can progress to chronic pain, which can cause other problems including depression, loss of motivation and sensory dysfunction....
JAN 21, 2020
Technology
JAN 21, 2020
Can artificial intelligence increase tuberculosis drug development?
It’s no secret that there is a shortage of tuberculosis drug development. To combat this issue, researchers at the University of Michigan designed a ...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
The unlikely pain killer
Pain can be anything a sunburn, a toothache, or a leg injury to name a few. The relievers that target our pain come in many colors—one being morphine...
JAN 21, 2020
Microbiology
JAN 21, 2020
Potential Therapeutics for Nipah Virus Are Identified
The fatality rate of Nipah virus has an estimated range of 40 to 75 percent...
Loading Comments...